Galacto-oligosaccharides and Intestinal Activity

Not Applicable

Completed

• Conditions: Healthy Adults
• Interventions: Dietary Supplement: Galacto-oligosaccharides; Dietary Supplement: Maltodextrin

• Registration Number: NCT04104360
• Lead Sponsor: Maastricht University Medical Center

Brief Summary

Dietary intake of galacto-oligosaccharides (GOS) may have beneficial effects on host health by affecting the microbiota composition and -activity. So far studies focused on analyses in fecal samples, while the primary site of carbohydrate fermentation is the proximal colon. To date, no studies have been performed in humans on the more proximal microbiota and the impact of fermentable carbohydrates. Further insights on the more proximal colonic microbiota would aid to targeted approaches to improve intestinal health. Therefore, we aim to study the effect of GOS on the intestinal microbiota composition and -activity in healthy adults, by sampling the more proximal human colon in a physiological condition. The primary objective of this study is to investigate the impact of four weeks GOS supplementation on intestinal microbiota composition and -activity, by sampling the proximal part of the human colon in a physiological condition. Furthermore, this study has four secondary objectives: First, to compare the intestinal microbiota composition and -activity of the proximal colon vs. distal colon at baseline and after four weeks GOS supplementation. Second, compare the luminal microbiota composition vs. mucosa adherent microbiota composition of the proximal vs. distal colon at baseline and after four weeks GOS supplementation. Third, monitor the effects of four weeks GOS supplementation on gastrointestinal symptoms. The study conforms to a randomized, double-blind, placebo-controlled, parallel design. Study population includes healthy human volunteers (male and female), 18-50 years of age. One intervention arm will include 7.2 grams of Vivinal® GOS Powder three times daily for four weeks. The other intervention arm subjects will receive placebo product (7.2 grams maltodextrin) three times daily for four weeks. At the start and end of the intervention period, several measurements will take place. The main study parameter is the change in microbial composition and -activity induced by GOS intervention.

Detailed Description

Not available

Study Timeline

• Study Start: 2019-09-17
• Study First Submitted: 2019-09-17
• Study First Submitted QC: 2019-09-23
• Study First Posted: 2019-09-26
• Primary Completion: 2024-08-15
• Study Completion: 2024-09-15
• Status Verified: 2025-03
• Last Update Submitted: 2025-03-20
• Last Update Posted: 2025-03-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 8

Inclusion Criteria

1. Based on medical history no gastrointestinal complaints can be defined.
2. Regular stool frequency ranging from 3 times/day - 3 times/week.
3. Body Mass Index (BMI) ≥ 20 and < 30 kg/m2.
4. Weight-stable for at least 90 days prior to participation (no change in bodyweight, i.e. < 3kg).
5. Willing to be informed in case of unexpected findings.

Exclusion Criteria

1. History of any disease or surgery interfering with the study aims, limiting participating or completing the study protocol.
2. Self-admitted human immunodeficiency virus-positive state.
3. Disease with a life expectancy shorter than 5 years.
4. Abdominal surgery interfering with gastrointestinal function, upon judgment of the medical doctor, who will decide on in- or exclusion based on the surgery applied.
5. Use of antibiotics within 90 days prior to the study.
6. Use of anticoagulation medication (except Ascal).
7. Use of proton pump inhibitors.
8. Use of other medication will be reviewed by a medical doctor, who will decide on in- or exclusion based on the drug(s) used.
9. Last colonoscopy within 90 days prior to the study.
10. Inadequate or painful (self-reported) colonoscopy undergone in the past.
11. American Society of Anesthesiologists (ASA) classification > 2.
12. Smoking.
13. Pregnancy or lactation.
14. Plan to lose weight or follow a specific diet within the study period.
15. Alcohol intake >14 units/week.
16. Use of laxatives within 14 days prior to the study.
17. Drug use.
18. Administration of probiotic or prebiotic supplements, investigational drugs or participation in any scientific intervention study, which may interfere with this study (to be decided by the principle investigator), in the 14 days prior to the study.
19. History of side effects towards intake of prebiotic supplements.
20. Self-admitted lactose intolerance.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Galacto-oligosacchardies	Galacto-oligosaccharides	During this period subjects will receive 7.2 grams of Vivinal GOS supplements three times daily for four weeks
Maltodextrin	Maltodextrin	During this period subjects will receive 7.2 grams of maltodextrin three times daily for four weeks

Primary Outcome Measures

Name	Time	Method
Microbial composition, as determined by state of the art (e.g. HiSeq) sequencing of 16S rRNA genes in colonic luminal/fecal samples and biopsies.	Change from baseline to four weeks supplementation	Total DNA will be extracted from fecal, small intestinal fluid and biopsy samples using the repeated bead-beating method. This method has been optimized and standardized for the extraction of total bacterial DNA from human fecal samples. Isolated DNA will be used for amplification of the V4 region of the collective 16S rRNA genes using barcoded primers, while fecal and intestinal DNA as target. Afterwards, the NG-Tax pipeline will be used for microbiota profiling. A variety of programs, such as R, and in house scripts will be used for bioinformatics analyses and multivariate statistics.
Microbial activity as determined by metatranscriptomics using RNA in colonic luminal samples and biopsies.	Change from baseline to four weeks supplementation	Microbiota activity profiling will be performed by metatranscriptomics. In short, RNA will be isolated from the luminal samples, followed by removal of rRNA and subsequent conversion of residual RNA into cDNA. The cDNA will serve as target for paired-end HiSeq sequencing. Obtained sequence reads will be phylogenetically and functionally annotated as described before. Dedicated R-scripts as well as programs such as iPath will be used for bioinformatic analyses, including metabolic mapping, and interpretation to determine which bacterial group is performing what activities. In addition, key metabolites of saccharolytic and protein fermentation (such as (branched) chain fatty acids) will be assessed by High-performance liquid chromatography (HPLC).

Trial Locations

Locations (1)

Maastricht University Medical Center; 🇳🇱 Maastricht, Limburg, Netherlands